Significance of expression of PD-L1, VEGF and CD8+ T cells in ovarian serous carcinoma: an Immunohistochemical study

: Background : Ovarian cancer is a lethal gynecological malignancy worldwide. The immune system plays a key role in preventing tumor development. Angiogenesis and immune evasion are vital for ovarian cancer progression and metastasis. Aim : This work aimed to evaluate the expression of PD-L1, VEGF and CD8 +T cells in ovarian serous carcinomas and correlate them with clinic-pathological variables. Material and methods : An Immunohistochemical study of PD-L1, VEGF and CD8+ T cells was performed on 50 cases of ovarian serous carcinomas. Results : PD-L1 & VEGF were over-expressed with statistical significance , in higher grade ( P <.01), advanced stage , case with lymph node metastasis and distant metastasis( P <.05) .Higher CD8+ T cells in epithelium and stroma was related to advanced stage, only intraepithelial CD8+ T cells was directly correlated with tumor grade & lymph node metastasis & stage ( P <.05). Positive correlation between PD-L1 & VEGF and Intraepithelial CD8+T cells was detected ( r =.048) Conclusion : Neoplastic cells in ovarian serous carcinomas-expressing PD-L1 and VEGF along with intraepithelial CD8+T cells-might expect poor prognosis. An association between PD-L1 and VEGF could predict their role in immune evasion.

• Publication year

  2023

• Venue

  Benha Medical Journal

• Publication date

  2023-09-17

• Fields of study

  Not labeled

• Identifiers
  DOI 10.21608/bmfj.2023.212530.1822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer

  2022cited by this paper
• Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer

  2021cited by this paper
• The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers.

  2021cited by this paper
• Cancer statistics for the year 2020: An overview

  2021cited by this paper
• Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response

  2021cited by this paper
• PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.

  2020cited by this paper
• Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

  2020cited by this paper
• Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

  2020cited by this paper
• Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression

  2020cited by this paper
• The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors

  2020cited by this paper
• Lymphocytes in Peritumoral Stroma: Evaluation in Epithelial Ovarian Neoplasms

  2020cited by this paper
• Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer

  2019cited by this paper
• Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

  2019cited by this paper
• Checkpoint inhibitors in ovarian cancer: A review of preclinical data

  2019cited by this paper
• Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer

  2019cited by this paper
• Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

  2018cited by this paper
• Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

  2018cited by this paper
• The Unique Molecular and Cellular Microenvironment of Ovarian Cancer

  2017cited by this paper
• PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

  2017cited by this paper
• VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms.

  2017cited by this paper
• Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

  2017cited by this paper
• Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?

  2016cited by this paper
• Anti-angiogenic agents in ovarian cancer: past, present, and future.

  2016cited by this paper
• Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

  2016cited by this paper
• IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

  2015cited by this paper
• Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

  2014cited by this paper
• Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.

  2011cited by this paper
• Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss

  2009cited by this paper
• Intraepithelial T cells and tumor proliferation

  2009cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma

  2004cited by this paper

• No citing papers are available for this paper.